Effect of Oral Magnesium Therapy on Constipation on Cerebral Palsy Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03471312|
Recruitment Status : Not yet recruiting
First Posted : March 20, 2018
Last Update Posted : March 20, 2018
|Condition or disease||Intervention/treatment|
|Magnesium Therapy on Cerebral Palsy Patients||Drug: Magnesium|
Children with cerebral palsy (CP) often experience many comorbidities such as constipation,which is considered a frequent problem in spastic (cp)children .It occurs due to reduced mobility, difficulties in feeding and as a side effect of many muscle relaxing medications.It is estimated that 74% of children with cerebral palsy suffer from constipation ,which necessitates use of laxatives. Magnesium sulfate has a famous role as being an osmotic laxative,which is the first step in the pharmacological treatment of constipation
• Mechanism of action of mg sulphate: They are poorly absorbed by the intestinal wall, which leads to intraluminal accumulation of hyperosmolar particles. This stimulates retention of water in the intestinal lumen, softening the stools and increasing peristalsis through intestinal distension. It acts by accelerating small intestinal transit both in fasting and in fed state and it tends to increase the frequency and weight of stools, compared with placebo.In addition ,It increases intraluminal secretion of cholecystokinin and increases nitric oxide (NO) release.
• Side effects of mg sulphate: Reducing the intestinal absorption of fat, protein and carbohydrates following solid meal ingestion
• other drugs used as laxative in cp and there side effects:
- Lactulose: it can lead to distention, bloating and excess flatus. In some individuals these side-effects may limit the use of this product.
Glycerin: is another small molecule that can exert osmotic activity in the colon. It is not absorbed by the colon and is used as a suppository to draw water into the rectum to produce a bowel movement. It is well absorbed by the small intestine, and hence cannot be taken by oral route.
- The aim of this study is to study the therapeutic and adverse effects of oral magnesium sulfate therapy on constipation in children with spastic cerebral palsy suffering from chronic constipation in neuro pediatric unit at Assiut University Hospital.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Effect of Oral Magnesium Therapy on Constipation on Children With Cerebral Palsy|
|Estimated Study Start Date :||May 1, 2018|
|Estimated Primary Completion Date :||October 30, 2018|
|Estimated Study Completion Date :||December 30, 2018|
treated with magnesium therapy
will receive magnesium sulphate 10 mg \kg \day as a single oral dose for one month duration
Other Name: placebo
treated with placebo drug
will receive placebo drug
Other Name: placebo
- EVALUATE THE EFFECT OF ORAL MAGNESIUM THERAPY ON CONSTIPATION IN CHILDREN WITH CEREBRAL PALSY BY A QUESTIONNAIRE [ Time Frame: baseline ]Evaluate the effect of oral magnesium therapy on constipation in children with spastic cerebral palsy suffering from chronic constipation in neuro pediatric unit at assiut university hospital by comparison of the percentage of improving cases in the 2 groups (first group using oral magnesium therapy . second group using placebo) by a questionnaire asking about amount , frequency and nature of stool
- Evaluate the main side effect of oral magnesium therapy (Diarrhea) [ Time Frame: baseline ]Evaluate the main side effect of oral magnesium therapy (Diarrhea) on constipation in children with spastic cerebral palsy suffering from chronic constipation in neuro pediatric unit at assiut university hospital by a questionnaire asking about amount , frequency and nature of stool
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03471312
|Contact: Nermeen abdelmageed||01145325756 ext email@example.com|
|Contact: ahlam firstname.lastname@example.org|